The Quantitative Decision-making Special Interest Group (QDM SIG) was formed in October 2017. It is a group of statisticians from industry and academia, with experience and interests in statistical methods for quantitative decision-making in drug development. The objectives of the SIG are:
| Corine Baayen (Lundbeck) |
| Thomas Blondel (Ceva) |
| Daniel Bratton (GSK) |
| Sarah Bray (Amgen) |
| Lasse Breuning Sluth (Lundbeck) |
| Alex Carlton (GSK) (Co-Chair) |
| Jacquie Christie (Sobi) |
| Paul Frewer (AstraZeneca) |
| Heiko Goette (Merck) |
| Tadhg Guerin (Theravance) (Co-Chair) |
| Gilles Guillot (CSL Behring) |
| Kimberley Hacquoil (Exploristics) |
| Serene Jiang (J&J) |
| Martin Johnson (UCB Pharma) |
Mette Krog Josiassen (Lundbeck) |
| Kevin Kunzmann (Boehringer Ingelheim) |
| John-Philip Lawo (CSL Behring) |
| Daniel Leibovitz (Incyte) |
| Jesper Madsen (Novo Nordisk) |
| Pavel Mozgunov (Cambridge University) |
Mads Mueller Pedersen (Lundbeck) |
| Caroline Petit (Merck) |
| Emmanuel Pham (Nova Discovery) |
| Franck Poitiers (Sanofi) |
| Gustaf Rydevik (UCB Pharma) |
| Gaëlle Saint-Hilary (Saryga) |
Nima Shiriati (Roche) |
| Guido Thömmes (Merck) |
| Katie Thorn (GSK) |
| Stefano Vezzoli (Chiesi Farmaceutici) |
| Stig Johan Wiklund (Captario) |
For further information, or to join the QDM SIG, please contact our Co-Chairs:
Alex Carlton (GSK) alex.l.carlton@gsk.com
Tadhg Guerin (Theravance) tguerin@theravance.com
This webinar will cover the history of cell/gene therapy, major regulatory advances, the role of quantitative scientists in drug development of these novel therapeutics, and discuss opportunities for innovation and product advancement.
Our monthly webinar explores examples of innovative data visualisations relevant to our day to day work. Each month a new dataset is provided from a clinical trial or other relevant example, and participants are invited to submit a graphic that communicates interesting and relevant characteristics of the data.
This networking event is aimed at statisticians that are new to the pharmaceutical industry who wish to meet colleagues from different companies and backgrounds.
An introductory course giving an overview of the pharmaceutical industry and the drug development process as a whole, aimed at those with 1-3 years' experience. It comprises of six 2-day sessions covering a range of topics including Research and Development, Toxicology, Data Management and the Role of a CRO, Clinical Trials, Reimbursement, and Marketing.
This 2-day course is designed to provide a comprehensive understanding of the regulatory guidelines affecting statisticians in the pharmaceutical industry, including the latest updates in the field. The course will cover key International Council for Harmonisation (ICH) guidelines and other key regional regulatory agency documents.
In this event, we’ll start with a general introduction to hierarchical composite endpoints and an overview of common analysis methods including win ratio, win odds, and net benefit. Then, the practical considerations will be illustrated through case studies from clinical trials in heart failure and chronic kidney disease. We conclude with a discussion and a Q&A.
A careers talk about medical statistics and how it plays a crucial role in developing new medicines
This webinar will discuss opportunities in applying causal inference methodology during the analysis of RCT data.
Lea Vaas will present how replacement of concurrent control animals by Virtual Control Groups (VCGs) in systemic toxicity studies may help in contributing to the 3R's principle of animal experimentation: Reduce, Refine, Replace.
This networking event is aimed at statisticians that are new to the pharmaceutical industry who wish to meet colleagues from different companies and backgrounds.
To provide expert statistical and strategic support to asset development programs in GSK Vaccines pipeline.
